Second clinical failure of Transgene in 2019
French Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Microbiota contribute to skin damage in cancer therapy
/in News/by Thomas GabrielczykNew research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions.
BIOncoTech Therapeutics and MSD combine cancer drugs
/in News/by Thomas GabrielczykMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Urokinase clears blot clots in stroke patients
/in News/by Thomas GabrielczykSwiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.
Sanofi buys Synthorx Inc for US$2.35bn
/in News/by Thomas GabrielczykSanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.
Meatable NV raises US$10m in seed funding
/in News/by Thomas GabrielczykMeatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the companys total funding to US$13m.
Big Pharma is cost driver of GAVI
/in News/by Thomas GabrielczykMédecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine
ImCheck Therapeutics SAS raises 48m
/in News/by Thomas GabrielczykT cell agonist specialist ImCheck Therapeutics will use 48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre amends license agreement with Puma Biotechnology
/in News/by Thomas GabrielczykPierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
European circular bioeconomy fund near closing
/in News/by Thomas GabrielczykThe European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the 250m EU circular bioeconomy fund.